This certificate equips learners with the technical expertise to design, optimize, and manufacture safe gene editing therapies using advanced vector systems.
- Strategize the implementation of genomic services by aligning gene editing technologies with regulatory frameworks and clinical service delivery models.
- Apply core gene editing technologies, such as CRISPR-Cas systems, to design precise genetic modifications for therapeutic targets.
- Engineer viral vectors with enhanced safety profiles by modifying capsid structures and regulatory elements to minimize biosafety risks.
- Select and optimize Adeno-Associated Virus (AAV) serotypes to achieve tissue-specific tropism and maximize transduction efficiency in target cells.
- Design non-viral nanoparticle delivery systems to facilitate the efficient cellular uptake of nucleic acids while reducing immunogenic responses.
- Analyze potential off-target effects using bioinformatics tools and experimental assays, and implement mitigation strategies to ensure genomic safety.
- Manage immunogenicity risks in gene therapy candidates by evaluating host immune responses and selecting appropriate countermeasures.
- Scale up the manufacturing process of gene therapy products from laboratory scale to Good Manufacturing Practice (GMP) compliance for clinical use.